These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38869976)

  • 1. Treatment for dry age-related macular degeneration: where we stand in 2024.
    Wheeler S; Mahmoudzadeh R; Randolph J
    Curr Opin Ophthalmol; 2024 Jun; ():. PubMed ID: 38869976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
    Khan H; Aziz AA; Sulahria H; Khan H; Ahmed A; Choudhry N; Narayanan R; Danzig C; Khanani AM
    Clin Ophthalmol; 2023; 17():321-327. PubMed ID: 36741078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of dry age-related macular degeneration: A review.
    Girgis S; Lee LR
    Clin Exp Ophthalmol; 2023 Nov; 51(8):835-852. PubMed ID: 37737509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in Imaging and Therapeutic Options for Dry Age-Related Macular Degeneration and Geographic Atrophy.
    Servillo A; Sacconi R; Oldoni G; Barlocci E; Tombolini B; Battista M; Fantaguzzi F; Rissotto F; Mularoni C; Parravano M; Zucchiatti I; Querques L; Bandello F; Querques G
    Ophthalmol Ther; 2024 Aug; 13(8):2067-2082. PubMed ID: 38833127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.
    Kim JB; Lad EM
    Drugs Aging; 2021 Jan; 38(1):17-27. PubMed ID: 33355716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration.
    Akyol E; Lotery A
    Biologics; 2020; 14():83-94. PubMed ID: 32982165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.
    Cabral de Guimaraes TA; Daich Varela M; Georgiou M; Michaelides M
    Br J Ophthalmol; 2022 Mar; 106(3):297-304. PubMed ID: 33741584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell-based therapies for age-related macular degeneration: current status and prospects.
    Mu Y; Zhao M; Su G
    Int J Clin Exp Med; 2014; 7(11):3843-52. PubMed ID: 25550892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Completed and Ongoing Complement Inhibitor Trials for Geographic Atrophy Secondary to Age-Related Macular Degeneration.
    Halawa OA; Lin JB; Miller JW; Vavvas DG
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Clinical and Preclinical Assessment of Clinical Trials for Dry Age-Related Macular Degeneration.
    Abidi M; Karrer E; Csaky K; Handa JT
    Ophthalmol Sci; 2022 Dec; 2(4):100213. PubMed ID: 36570624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current therapeutic developments in atrophic age-related macular degeneration.
    Hanus J; Zhao F; Wang S
    Br J Ophthalmol; 2016 Jan; 100(1):122-7. PubMed ID: 26553922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
    Borchert GA; Shamsnajafabadi H; Hu ML; De Silva SR; Downes SM; MacLaren RE; Xue K; Cehajic-Kapetanovic J
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry age-related macular degeneration: recent progress of therapeutic approaches.
    Kuno N; Fujii S
    Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.
    Waugh N; Loveman E; Colquitt J; Royle P; Yeong JL; Hoad G; Lois N
    Health Technol Assess; 2018 May; 22(27):1-168. PubMed ID: 29846169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry Age-Related Macular Degeneration Pharmacology.
    Wright CB; Ambati J
    Handb Exp Pharmacol; 2017; 242():321-336. PubMed ID: 27900609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects.
    Danis RP; Lavine JA; Domalpally A
    Clin Ophthalmol; 2015; 9():2159-74. PubMed ID: 26640366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems.
    Jiménez-Gómez Y; Alba-Molina D; Blanco-Blanco M; Pérez-Fajardo L; Reyes-Ortega F; Ortega-Llamas L; Villalba-González M; Fernández-Choquet de Isla I; Pugliese F; Stoikow I; González-Andrades M
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-Related Macular Degeneration: An Exponentially Emerging Imminent Threat of Visual Impairment and Irreversible Blindness.
    Chaudhuri M; Hassan Y; Bakka Vemana PPS; Bellary Pattanashetty MS; Abdin ZU; Siddiqui HF
    Cureus; 2023 May; 15(5):e39624. PubMed ID: 37388610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the management of dry age-related macular degeneration: A review.
    Bandello F; Sacconi R; Querques L; Corbelli E; Cicinelli MV; Querques G
    F1000Res; 2017; 6():245. PubMed ID: 28529701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry age-related macular degeneration: A currently unmet clinical need.
    Girmens JF; Sahel JA; Marazova K
    Intractable Rare Dis Res; 2012 Aug; 1(3):103-14. PubMed ID: 25343081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.